Profil
Fernando Doñate worked as the Director of Preclinical Research at Proacta, Inc. from 2008 to 2010.
He also worked as the Associate Director of Biology at Attenuon, LLC.
Dr. Doñate earned a doctorate degree from the University of Missouri in 1994 and an undergraduate degree from Universidad Complutense de Madrid in 1988.
Ehemalige bekannte Positionen von Fernando Doñate
| Unternehmen | Position | Ende |
|---|---|---|
| Attenuon, LLC | Corporate Officer/Principal | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Fernando Doñate
| University of Missouri | Doctorate Degree |
| Universidad Complutense de Madrid | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
| Attenuon, LLC |
